When you’re diagnosed with lung cancer, your doctor will classify it as one of two types: small cell lung cancer or non-small-cell lung cancer (NSCLC). NSCLC is far more common. About 85% of all lung ...
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations) Hybrid capture–based comprehensive genomic ...
Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort. The study reported a median duration of response of 8.7 months and a ...
The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) In the efficacy population (n = 81), the ...
Hereditary conditions cause those who suffer from them to live shorter lives with traumatic health issues. Because of this, researchers in the field of genetics are constantly exploring and developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results